RepliCel Life Sciences EV/EBITDA
What is the EV/EBITDA of RepliCel Life Sciences?
The EV/EBITDA of RepliCel Life Sciences, Inc. is N/A
What is the definition of EV/EBITDA?
EV/EBITDA is enterprise value divided by earnings before interest, tax, depreciation, and amortization. It is a measure of how expensive a stock is and is more frequently valid for comparisons across companies than the price to earnings ratio. It measures the price (in the form of enterprise value) an investor pays for the benefit of the company’s cash flow (in the form of EBITDA).
= enterprise value / EBITDA
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA of companies in the Health Care sector on TSXV compared to RepliCel Life Sciences
What does RepliCel Life Sciences do?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Companies with ev/ebitda similar to RepliCel Life Sciences
- Nuheara has EV/EBITDA of N/A
- Acerus Pharmaceuticals has EV/EBITDA of N/A
- Darelle Online Solutions has EV/EBITDA of N/A
- GURU Organic has EV/EBITDA of N/A
- Sinofortune has EV/EBITDA of N/A
- The Limestone Boat has EV/EBITDA of N/A
- RepliCel Life Sciences has EV/EBITDA of N/A
- Leviathan Gold has EV/EBITDA of N/A
- Intrepid Metals Corp has EV/EBITDA of N/A
- Centogene N.V. Eo ,12 has EV/EBITDA of N/A
- Comprehensive Healthcare Systems has EV/EBITDA of N/A
- Property Connect has EV/EBITDA of N/A
- Da Sen has EV/EBITDA of N/A